ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

16 links0 made here, not in the record37 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05159245The Finnish National Studyto Facilitate PatientAccess to TargetedAnti-cancer DrugsHelsinki University Central HoPhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 10 · ClinicalTrials.gov record · Version of 2026-11-10Version of 2026-11-10CONDITIONSHematologic NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSAlectinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCobimetinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedHhAntag691Entry “Vismodegib”, read by our name …›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTrastuzumabEntry “Trastuzumab+Pertuzumab”, read …›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPertuzumabEntry “Trastuzumab+Pertuzumab”, read …›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedEntrectinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAtezolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedVemurafenibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedRegorafenibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedApalutamideIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAbemaciclibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · TestedBackground · optionTepotinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDabrafenibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTrametinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPemigatinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Alectinib

From the registry record3 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Alectinib”the record gives no role
→judged=agrees=agrees
How the 3 judgments split100%of judgments with a known value say Tested
Tested · 3

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2AlectinibClaude Opus 5.5TestedReplaced
Nov 2CobimetinibClaude Opus 5.5TestedReplaced
Nov 2HhAntag691Claude Opus 5.5TestedCurrent
Nov 2TrastuzumabClaude Opus 5.5TestedCurrent
Nov 2PertuzumabClaude Opus 5.5TestedReplaced
Nov 2EntrectinibClaude Opus 5.5TestedReplaced
Nov 2AtezolizumabClaude Opus 5.5TestedReplaced
Nov 2VemurafenibClaude Opus 5.5TestedCurrent
Nov 2RegorafenibClaude Opus 5.5TestedCurrent
Nov 2ApalutamideClaude Opus 5.5TestedCurrent
Nov 2AbemaciclibClaude Opus 5.5TestedReplaced
Nov 2TepotinibClaude Opus 5.5TestedCurrent
Nov 2DabrafenibClaude Opus 5.5TestedCurrent
Nov 2TrametinibClaude Opus 5.5TestedCurrent
Nov 2PemigatinibClaude Opus 5.5TestedCurrent
Nov 3AlectinibClaude Opus 5.5TestedCurrent
Nov 3CobimetinibClaude Opus 5.5TestedCurrent
Nov 3PertuzumabClaude Opus 5.5TestedCurrent
Nov 3EntrectinibClaude Opus 5.5TestedCurrent
Nov 3AtezolizumabClaude Opus 5.5TestedCurrent
Nov 3AbemaciclibClaude Opus 5.5Background · optionCurrent
Nov 10The record itselfClinicalTrials.gov recordVersion of 2026-11-10Record change
Nov 18AlectinibRule based · role ruleTestedAgrees
Nov 18CobimetinibRule based · role ruleTestedAgrees
Nov 18HhAntag691Rule based · role ruleTestedAgrees
Nov 18TrastuzumabRule based · role ruleTestedAgrees
Nov 18PertuzumabRule based · role ruleTestedAgrees
Nov 18EntrectinibRule based · role ruleTestedAgrees
Nov 18AtezolizumabRule based · role ruleTestedAgrees
Nov 18VemurafenibRule based · role ruleTestedAgrees
Nov 18RegorafenibRule based · role ruleTestedAgrees
Nov 18ApalutamideRule based · role ruleTestedAgrees
Nov 18AbemaciclibRule based · role ruleTestedOverridden
Nov 18TepotinibRule based · role ruleTestedAgrees
Nov 18DabrafenibRule based · role ruleTestedAgrees
Nov 18TrametinibRule based · role ruleTestedAgrees
Nov 18PemigatinibRule based · role ruleTestedAgrees
As of nowHematologic NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.